Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis Shuai ShaoGang Wang Commentary Open access 08 October 2022 Pages: 2627 - 2635
Artificial Intelligence in Dermatology: Challenges and Perspectives Konstantinos LiopyrisStamatios GregoriouAlexandros J. Stratigos Commentary Open access 28 October 2022 Pages: 2637 - 2651
Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review Ahmad N. FasseehBaher ElezbawyZoltán Kaló Review Open access 05 October 2022 Pages: 2653 - 2668
New Developing Treatments for Molluscum Contagiosum Francesco LacarrubbaGiuseppe MicaliAnna Elisa Verzì Review Open access 14 October 2022 Pages: 2669 - 2678
The Impact of Global Health Disparities on Atopic Dermatitis in Displaced Populations: Narrowing the Health Equity Gap for Patients with Skin of Color Sami JelousiDivya SharmaJenny E. Murase Review Open access 19 October 2022 Pages: 2679 - 2689
Current and Emerging Therapies in Pediatric Atopic Dermatitis Hadley JohnsonJiaDe Yu Review Open access 18 October 2022 Pages: 2691 - 2703
Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics Nikita S. WongTaylor M. AdlamMehdi Farshchian Review Open access 03 November 2022 Pages: 2705 - 2714
A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians Anastasia DrakosRonald Vender Review Open access 01 November 2022 Pages: 2715 - 2730
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials Jonathan I. SilverbergMark BoguniewiczNoah A. Levit Original Research Open access 21 October 2022 Pages: 2731 - 2746
Predicting Clinical Remission of Chronic Urticaria Using Random Survival Forests: Machine Learning Applied to Real-World Data Irina PivnevaMaria-Magdalena BalpWeily Soong Original Research Open access 27 October 2022 Pages: 2747 - 2763
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials Norito KatohYasushi TakitaHidehisa Saeki Original Research Open access 18 October 2022 Pages: 2765 - 2779
Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study Christiane QuerfeldWinnie W. NelsonLarisa J. Geskin Original Research Open access 25 October 2022 Pages: 2781 - 2795
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry Benjamin LockshinRyan W. HarrisonRussel T. Burge Original Research Open access 04 November 2022 Pages: 2797 - 2815
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS) Jonathan I. SilverbergEric L. SimpsonYael A. Leshem Original Research Open access 04 November 2022 Pages: 2817 - 2827
Multidisciplinary Rheuma–Derma Clinics: 5 Years of Experience at the San Marco Hospital in Catania Rosario FotiGiorgia GiuffridaRocco De Pasquale Original Research Open access 04 November 2022 Pages: 2829 - 2837
Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis Amy S. PallerGil YosipovitchDimittri Delevry Brief Report Open access 21 October 2022 Pages: 2839 - 2850
Characteristics of Giant Nodular Melanomas in Special Locations: a Case Series and Review of the Literature Grażyna Kamińska-WinciorekKatarzyna GalwasIris Zalaudek Case Series Open access 04 November 2022 Pages: 2851 - 2862
Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis Dan PettittMichael PlotnickJoshua Gagne Letter Open access 21 October 2022 Pages: 2863 - 2866
A Response to: Letter to the Editor Regarding Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis April W. ArmstrongAhmed M. SolimanLuis Puig Letter Open access 21 October 2022 Pages: 2867 - 2870
Correction to: Leg Ulcer Therapy by Local Injection of Autologous Growth Factors: Results of a Pilot Study Petr ŠímaValér DžupaSpyridon Gkalpakiotis Correction Open access 21 October 2022 Pages: 2871 - 2871